Barclays Believes IQVIA Holdings Inc (IQV) Won’t Stop Here
Barclays analyst Jack Meehan maintained a Buy rating on IQVIA Holdings Inc (IQV) yesterday and set a price target of $155. The company’s shares closed yesterday at $141.13, close to its 52-week high of $143.42.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 5.9% and a 61.6% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Syneos Health Inc, and Myriad Genetics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings Inc with a $153.17 average price target, representing an 8.5% upside. In a report released today, UBS also reiterated a Buy rating on the stock with a $170 price target.
See today’s analyst top recommended stocks >>
IQVIA Holdings Inc’s market cap is currently $28.55B and has a P/E ratio of 23.82. The company has a Price to Book ratio of 3.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IQVIA Holdings, Inc. is a biotechnology company, which engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries. The company was founded by Dennis Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.